Form 4: Alector CFO Acquires 65,000 RSUs, 195,000 Stock Options

Alector's Chief Business Officer and Interim CFO, Neil Lindsay Berkley, acquired 65,000 Restricted Stock Units and 195,000 employee stock options.

Summary

• Neil Lindsay Berkley, Alector's Chief Business Officer and Interim CFO, acquired 65,000 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs were acquired at a price of $0 and will vest in 12 equal quarterly installments starting December 1, 2025.
• Berkley also acquired 195,000 employee stock options with an exercise price of $1.31 per share.
• These stock options will vest in 48 equal monthly installments beginning on December 10, 2025, and expire on November 9, 2035.
• The transactions occurred on November 10, 2025, and were made pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Berkley beneficially owns 411,570 shares of common stock directly and 195,000 derivative securities (options) directly.

Sentiment

Score: 7

Explanation: The filing reports a standard executive equity grant, which is generally a positive signal of management's alignment with shareholder interests and confidence in future performance, though it doesn't reflect operational results.

Positives

• A senior executive, Neil Lindsay Berkley, is increasing his equity stake in Alector, Inc. through RSU and stock option grants, aligning his interests with shareholders.
• The grants are part of a pre-arranged Rule 10b5-1(c) plan, indicating a structured approach to equity compensation.

Risks

• The value of the RSUs and stock options is tied to the future performance of Alector's stock, meaning the actual realized value could be lower if the stock price declines.
• The long vesting schedules (12 quarterly installments for RSUs, 48 monthly installments for options) mean the executive's full ownership is contingent on continued employment and company performance over several years.

Future Outlook

The grants of RSUs and stock options with multi-year vesting schedules indicate an expectation of continued employment and a belief in the company's long-term growth potential by the executive and the board.

Industry Context

Equity compensation, particularly through RSUs and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. The vesting schedules are typical for long-term incentive plans.

Comparison to Industry Standards

• The use of RSUs and stock options as executive compensation is a standard practice across the biotech industry, comparable to companies like Biogen, Amgen, or Regeneron, which frequently use similar long-term incentive structures to align executive interests with shareholder value.
• The vesting periods (12 quarters for RSUs, 48 months for options) are typical for executive grants, designed to encourage long-term commitment and performance, similar to what is observed at peer companies in the sector.
• The exercise price of $1.31 for the options would typically be set at the fair market value of the stock on the grant date, a common practice to ensure compliance and provide incentive for future stock price appreciation.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through equity ownership. Potential for dilution from future RSU conversions and option exercises, though this is standard for equity compensation plans.
• Employees: Reflects the company's ongoing use of equity compensation as part of its overall remuneration strategy.
• Management: Neil Lindsay Berkley's compensation package is enhanced, providing long-term incentives.

Next Steps

• The RSUs will begin vesting quarterly on December 1, 2025.
• The stock options will begin vesting monthly on December 10, 2025.

Key Dates

Recommendation

This Form 4 reports a routine equity compensation grant to a senior executive, which is a standard practice for public companies. While it signals management's alignment with shareholder interests, it does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Alector, ALEC, Form 4, Insider Trading, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Executive Compensation, Neil Lindsay Berkley, Chief Business Officer, Interim CFO, Rule 10b5-1